Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkx475PMID 29244129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration

  2017cited by this paper
• Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection

  2017cited by this paper
• Review of doing Bayesian data analysis: a tutorial with R, JAGS, and Stan (second edition)

  2017cited by this paper
• The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration

  2017cited by this paper
• Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells

  2017cited by this paper
• Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.

  2017cited by this paper
• HIV-1 Latency and Eradication: Past, Present and Future.

  2016cited by this paper
• Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.

  2016cited by this paper
• Establishment and stability of the latent HIV-1 DNA reservoir

  2016cited by this paper
• Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.

  2016cited by this paper
• Might dolutegravir be part of a functional cure for HIV?

  2016cited by this paper
• Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

  2016cited by this paper
• HIV-1 integration landscape during latent and active infection.

  2015cited by this paper
• Persistent HIV-1 replication maintains the tissue reservoir during therapy

  2015cited by this paper
• Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

  2015cited by this paper
• HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells

  2015cited by this paper
• Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

  2015cited by this paper
• Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy.

  2015cited by this paper
• The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

  2014cited by this paper
• Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency

  2014cited by this paper
• Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.

  2014cited by this paper
• Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.

  2014cited by this paper
• Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

  2014cited by this paper
• HIV-1 Tropism Dynamics and Phylogenetic Analysis from Longitudinal Ultra-Deep Sequencing Data of CCR5- and CXCR4-Using Variants

  2014cited by this paper
• The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

  2013cited by this paper
• Cellular and molecular mechanisms involved in the establishment of HIV-1 latency

  2013cited by this paper
• Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

  2013cited by this paper
• Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

  2013cited by this paper
• A Single HIV-1 Cluster and a Skewed Immune Homeostasis Drive the Early Spread of HIV among Resting CD4+ Cell Subsets within One Month Post-Infection

  2013cited by this paper
• Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

  2013cited by this paper
• Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

  2012cited by this paper
• Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection

  2012cited by this paper
• Systematic exploration of error sources in pyrosequencing flowgram data

  2011cited by this paper
• Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

  2011cited by this paper
• No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

  2010cited by this paper
• Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen

  2010cited by this paper
• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

  2010cited by this paper
• HIV-1 Populations in Semen Arise through Multiple Mechanisms

  2010cited by this paper
• The immune response during acute HIV-1 infection: clues for vaccine development

  2009cited by this paper
• LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)

  2009cited by this paper
• Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients

  2009cited by this paper
• HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

  2009cited by this paper
• Kinetics of Expansion of Epitope-Specific T Cell Responses during Primary HIV-1 Infection1

  2009cited by this paper
• Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

  2008cited by this paper
• Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

  2003cited by this paper
• Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence

  2003cited by this paper
• The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

  2003cited by this paper
• Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

  1998cited by this paper
• Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission

  1996cited by this paper

• Differential associations of anti-cytomegalovirus antibodies and soluble CD14 levels with immunosenescence in people living with HIV on long term antiretroviral therapy

  2024cites this paper
• Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen

  2024cites this paper
• Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen

  2023cites this paper
• T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer

  2022cites this paper
• Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART

  2020cites this paper
• HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol

  2020cites this paper
• Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.

  2020cites this paper
• Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice

  2019cites this paper
• Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

  2019influential citation
• Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults

  2018cites this paper
• Impact des inhibiteurs de l'intégrase sur la constitution et la compartimentalisation du réservoir viral

  2018cites this paper